Healthcare -
Biotechnology - NASDAQ - US
$ 5.33
0.947 %
$ 237 M
Market Cap
-1.7
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Verastem, Inc.
| Current Assets | 144 M |
| Cash & Short-Term Investments | 137 M |
| Receivables | 0 |
| Other Current Assets | 6.55 M |
| Non-Current Assets | 6.04 M |
| Long-Term Investments | 241 K |
| PP&E | 1.21 M |
| Other Non-Current Assets | 4.59 M |
| Current Liabilities | 26.4 M |
| Accounts Payable | 7.18 M |
| Short-Term Debt | 1.88 M |
| Other Current Liabilities | 17.3 M |
| Non-Current Liabilities | 44.8 M |
| Long-Term Debt | 40.6 M |
| Other Non-Current Liabilities | 4.19 M |
EFFICIENCY
Earnings Waterfall
Verastem, Inc.
| Revenue | 0 |
| Cost Of Revenue | 62 K |
| Gross Profit | -62 K |
| Operating Expenses | 92 M |
| Operating Income | -92.1 M |
| Other Expenses | -4.72 M |
| Net Income | -87.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Verastem, Inc.
| Net Income | -87.4 M |
| Depreciation & Amortization | -113 K |
| Capital Expenditures | 7 K |
| Stock-Based Compensation | 5.86 M |
| Change in Working Capital | -957 K |
| Others | -4.84 M |
| Free Cash Flow | -86.5 M |
Wall Street Analysts Price Targets
Verastem, Inc.
Wall Street analysts predict an average 1-year price target for VSTM of $9 , with forecasts ranging from
a
low of
$5 to a high of $13 .
VSTM Lowest Price Target
Wall Street Target
5 USD
-6.19%
VSTM Average Price Target
Wall Street Target
9 USD
68.86%
VSTM Highest Price Target
Wall Street Target
13 USD
143.90%
4. DIVIDEND
ANALYSIS
VSTM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Verastem, Inc.
Sold
0-3 MONTHS
11.4 K USD 4
3-6 MONTHS
12.3 K USD 4
6-9 MONTHS
6.31 K USD 4
9-12 MONTHS
145 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 month ago
Dec 20, 2024
|
Sell 282
USD
|
Calkins Daniel
Chief Financial Officer
|
- 65
|
4.34 USD |
|
3 weeks ago
Dec 24, 2024
|
Sell 109
USD
|
Calkins Daniel
Chief Financial Officer
|
- 28
|
3.91 USD |
|
1 month ago
Dec 16, 2024
|
Sell 1.29 K
USD
|
Gagnon Robert E.
Director
|
- 285
|
4.54 USD |
|
1 month ago
Dec 19, 2024
|
Sell 568
USD
|
Gagnon Robert E.
Director
|
- 130
|
4.37 USD |
|
1 month ago
Dec 16, 2024
|
Sell 2.7 K
USD
|
Stuglik Brian M
Director
|
- 595
|
4.54 USD |
|
1 month ago
Dec 19, 2024
|
Sell 1.46 K
USD
|
Stuglik Brian M
Director
|
- 334
|
4.37 USD |
|
1 month ago
Dec 16, 2024
|
Sell 1.11 K
USD
|
Paterson Dan
President and CEO
|
- 244
|
4.54 USD |
|
1 month ago
Dec 19, 2024
|
Sell 800
USD
|
Paterson Dan
President and CEO
|
- 183
|
4.37 USD |
|
2 months ago
Nov 05, 2024
|
Sell 3.12 K
USD
|
Paterson Dan
President and CEO
|
- 812
|
3.84 USD |
|
3 months ago
Oct 07, 2024
|
Sell 17.2
USD
|
Calkins Daniel
Chief Financial Officer
|
- 6
|
2.86 USD |
|
3 months ago
Sep 20, 2024
|
Sell 182
USD
|
Calkins Daniel
Chief Financial Officer
|
- 65
|
2.8 USD |
|
3 months ago
Sep 24, 2024
|
Sell 75
USD
|
Calkins Daniel
Chief Financial Officer
|
- 28
|
2.68 USD |
|
4 months ago
Sep 19, 2024
|
Sell 365
USD
|
Gagnon Robert E.
Director
|
- 131
|
2.79 USD |
|
4 months ago
Sep 19, 2024
|
Sell 513
USD
|
Paterson Dan
President and CEO
|
- 184
|
2.79 USD |
|
4 months ago
Sep 19, 2024
|
Sell 937
USD
|
Stuglik Brian M
Director
|
- 336
|
2.79 USD |
|
4 months ago
Sep 16, 2024
|
Sell 804
USD
|
Gagnon Robert E.
Director
|
- 287
|
2.8 USD |
|
4 months ago
Sep 16, 2024
|
Sell 1.68 K
USD
|
Stuglik Brian M
Director
|
- 600
|
2.8 USD |
|
4 months ago
Sep 16, 2024
|
Sell 689
USD
|
Paterson Dan
President and CEO
|
- 246
|
2.8 USD |
|
5 months ago
Aug 05, 2024
|
Sell 7.01 K
USD
|
Paterson Dan
President and CEO
|
- 3245
|
2.16 USD |
|
6 months ago
Jul 09, 2024
|
Sell 18.3
USD
|
Calkins Daniel
Chief Financial Officer
|
- 7
|
2.62 USD |
|
6 months ago
Jun 24, 2024
|
Sell 88.2
USD
|
Calkins Daniel
Chief Financial Officer
|
- 28
|
3.15 USD |
|
7 months ago
Jun 20, 2024
|
Sell 212
USD
|
Calkins Daniel
Chief Financial Officer
|
- 67
|
3.16 USD |
|
7 months ago
Jun 20, 2024
|
Sell 421
USD
|
Gagnon Robert E.
Director
|
- 131
|
3.21 USD |
|
7 months ago
Jun 17, 2024
|
Sell 988
USD
|
Gagnon Robert E.
Director
|
- 283
|
3.49 USD |
|
7 months ago
Jun 20, 2024
|
Sell 587
USD
|
Paterson Dan
President and CEO
|
- 183
|
3.21 USD |
|
7 months ago
Jun 17, 2024
|
Sell 852
USD
|
Paterson Dan
President and CEO
|
- 244
|
3.49 USD |
|
7 months ago
Jun 20, 2024
|
Sell 1.08 K
USD
|
Stuglik Brian M
Director
|
- 335
|
3.21 USD |
|
7 months ago
Jun 17, 2024
|
Sell 2.07 K
USD
|
Stuglik Brian M
Director
|
- 593
|
3.49 USD |
|
9 months ago
Apr 05, 2024
|
Sell 65.2
USD
|
Calkins Daniel
Chief Financial Officer
|
- 6
|
10.87 USD |
|
9 months ago
Mar 25, 2024
|
Sell 300
USD
|
Calkins Daniel
Chief Financial Officer
|
- 25
|
12.02 USD |
|
10 months ago
Mar 20, 2024
|
Sell 609
USD
|
Calkins Daniel
Chief Financial Officer
|
- 55
|
11.07 USD |
|
10 months ago
Mar 18, 2024
|
Sell 3.03 K
USD
|
Gagnon Robert E.
Director
|
- 283
|
10.71 USD |
|
10 months ago
Mar 19, 2024
|
Sell 1.35 K
USD
|
Gagnon Robert E.
Director
|
- 130
|
10.38 USD |
|
10 months ago
Mar 18, 2024
|
Sell 2.61 K
USD
|
Paterson Dan
President and CEO
|
- 244
|
10.71 USD |
|
10 months ago
Mar 19, 2024
|
Sell 1.89 K
USD
|
Paterson Dan
President and CEO
|
- 182
|
10.38 USD |
|
10 months ago
Mar 18, 2024
|
Sell 5.75 K
USD
|
Stuglik Brian M
Director
|
- 537
|
10.71 USD |
|
10 months ago
Mar 19, 2024
|
Sell 2.83 K
USD
|
Stuglik Brian M
Director
|
- 273
|
10.38 USD |
|
11 months ago
Feb 06, 2024
|
Sell 126 K
USD
|
Gagnon Robert E.
Director
|
- 9204
|
13.7 USD |
|
7 years ago
Sep 05, 2017
|
Bought
7.68 K USD
|
Rowinsky Eric K
Director
|
+ 2000
|
3.84 USD |
|
1 year ago
Jan 12, 2024
|
Sell 101 K
USD
|
Gagnon Robert E.
Director
|
- 9204
|
10.95 USD |
|
1 year ago
Jan 05, 2024
|
Sell 51
USD
|
Calkins Daniel
Chief Financial Officer
|
- 6
|
8.5 USD |
|
1 year ago
Dec 26, 2023
|
Sell 202
USD
|
Calkins Daniel
Chief Financial Officer
|
- 25
|
8.08 USD |
|
1 year ago
Dec 20, 2023
|
Sell 452
USD
|
Calkins Daniel
Chief Financial Officer
|
- 57
|
7.93 USD |
|
1 year ago
Dec 18, 2023
|
Sell 2.17 K
USD
|
Gagnon Robert E.
Director
|
- 284
|
7.64 USD |
|
1 year ago
Dec 19, 2023
|
Sell 1 K
USD
|
Gagnon Robert E.
Director
|
- 130
|
7.73 USD |
|
1 year ago
Dec 18, 2023
|
Sell 1.86 K
USD
|
Paterson Dan
President and CEO
|
- 244
|
7.64 USD |
|
1 year ago
Dec 19, 2023
|
Sell 1.41 K
USD
|
Paterson Dan
President and CEO
|
- 183
|
7.73 USD |
|
1 year ago
Dec 18, 2023
|
Sell 3.72 K
USD
|
Stuglik Brian M
Director
|
- 487
|
7.64 USD |
|
1 year ago
Dec 19, 2023
|
Sell 2.12 K
USD
|
Stuglik Brian M
Director
|
- 274
|
7.73 USD |
|
1 year ago
Oct 05, 2023
|
Sell 36.5
USD
|
Calkins Daniel
Vice President of Finance
|
- 5
|
7.3 USD |
|
1 year ago
Sep 21, 2023
|
Sell 2.16 K
USD
|
Calkins Daniel
Vice President of Finance
|
- 232
|
9.31 USD |
|
1 year ago
Sep 25, 2023
|
Sell 235
USD
|
Calkins Daniel
Vice President of Finance
|
- 25
|
9.4 USD |
|
1 year ago
Sep 18, 2023
|
Sell 2.38 K
USD
|
Paterson Dan
President and CEO
|
- 240
|
9.91 USD |
|
1 year ago
Sep 19, 2023
|
Sell 1.8 K
USD
|
Paterson Dan
President and CEO
|
- 183
|
9.84 USD |
|
1 year ago
Sep 18, 2023
|
Sell 2.75 K
USD
|
Gagnon Robert E.
Director
|
- 278
|
9.91 USD |
|
1 year ago
Sep 19, 2023
|
Sell 1.28 K
USD
|
Gagnon Robert E.
Director
|
- 130
|
9.84 USD |
|
1 year ago
Sep 18, 2023
|
Sell 4.74 K
USD
|
Stuglik Brian M
Director
|
- 478
|
9.91 USD |
|
1 year ago
Sep 19, 2023
|
Sell 2.7 K
USD
|
Stuglik Brian M
Director
|
- 274
|
9.84 USD |
|
1 year ago
Jul 06, 2023
|
Sell 40.1
USD
|
Calkins Daniel
Vice President of Finance
|
- 5
|
8.02 USD |
|
1 year ago
Jun 26, 2023
|
Sell 212
USD
|
Calkins Daniel
Vice President of Finance
|
- 26
|
8.17 USD |
|
1 year ago
Jun 16, 2023
|
Sell 2.42 K
USD
|
Paterson Dan
President and COO
|
- 244
|
9.92 USD |
|
1 year ago
Jun 20, 2023
|
Sell 1.88 K
USD
|
Paterson Dan
President and COO
|
- 183
|
10.3 USD |
|
1 year ago
Jun 16, 2023
|
Sell 2.81 K
USD
|
Gagnon Robert E.
Director
|
- 283
|
9.92 USD |
|
1 year ago
Jun 20, 2023
|
Sell 1.34 K
USD
|
Gagnon Robert E.
Director
|
- 130
|
10.3 USD |
|
1 year ago
Jun 16, 2023
|
Sell 4.83 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 487
|
9.92 USD |
|
1 year ago
Jun 20, 2023
|
Sell 2.83 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 275
|
10.3 USD |
|
1 year ago
Apr 05, 2023
|
Sell 27.8
USD
|
Calkins Daniel
Vice President of Finance
|
- 75
|
0.37 USD |
|
1 year ago
Mar 24, 2023
|
Sell 159
USD
|
Calkins Daniel
Vice President of Finance
|
- 378
|
0.42 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.46 K
USD
|
Gagnon Robert E.
Director
|
- 3654
|
0.4 USD |
|
1 year ago
Mar 20, 2023
|
Sell 716
USD
|
Gagnon Robert E.
Director
|
- 1664
|
0.43 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.26 K
USD
|
Paterson Dan
President and COO
|
- 3138
|
0.4 USD |
|
1 year ago
Mar 20, 2023
|
Sell 1.01 K
USD
|
Paterson Dan
President and COO
|
- 2339
|
0.43 USD |
|
1 year ago
Mar 16, 2023
|
Sell 2.51 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 6276
|
0.4 USD |
|
1 year ago
Mar 20, 2023
|
Sell 1.51 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 3508
|
0.43 USD |
|
2 years ago
Jan 05, 2023
|
Sell 31.8
USD
|
Calkins Daniel
Vice President of Finance
|
- 74
|
0.43 USD |
|
2 years ago
Dec 27, 2022
|
Sell 411
USD
|
Calkins Daniel
Vice President of Finance
|
- 1246
|
0.33 USD |
|
2 years ago
Dec 16, 2022
|
Sell 6.27 K
USD
|
Paterson Dan
President and COO
|
- 15676
|
0.4 USD |
|
2 years ago
Dec 19, 2022
|
Sell 1.09 K
USD
|
Paterson Dan
President and COO
|
- 2954
|
0.37 USD |
|
2 years ago
Dec 16, 2022
|
Sell 4.96 K
USD
|
Gagnon Robert E.
Director
|
- 12408
|
0.4 USD |
|
2 years ago
Dec 19, 2022
|
Sell 529
USD
|
Gagnon Robert E.
Director
|
- 1429
|
0.37 USD |
|
2 years ago
Dec 16, 2022
|
Sell 10.1 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 25162
|
0.4 USD |
|
2 years ago
Dec 19, 2022
|
Sell 1.32 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 3556
|
0.37 USD |
|
2 years ago
Sep 19, 2022
|
Sell 3.79 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 3355
|
1.13 USD |
|
2 years ago
Sep 19, 2022
|
Sell 1.52 K
USD
|
Gagnon Robert E.
Chief Financial Officer
|
- 1348
|
1.13 USD |
|
2 years ago
Aug 01, 2022
|
Sell 6.33 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 5858
|
1.08 USD |
|
2 years ago
Jun 21, 2022
|
Sell 3.08 K
USD
|
Paterson Dan
President and COO
|
- 2701
|
1.14 USD |
|
2 years ago
Jun 21, 2022
|
Sell 3.83 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 3362
|
1.14 USD |
|
2 years ago
Jun 21, 2022
|
Sell 1.54 K
USD
|
Gagnon Robert E.
Chief Financial Officer
|
- 1351
|
1.14 USD |
|
2 years ago
May 14, 2022
|
Sell 5.14 K
USD
|
Paterson Dan
President and COO
|
- 4988
|
1.03 USD |
|
2 years ago
May 14, 2022
|
Sell 14.2 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 13794
|
1.03 USD |
|
2 years ago
May 14, 2022
|
Sell 17.1 K
USD
|
Gagnon Robert E.
Chief Financial Officer
|
- 16627
|
1.03 USD |
|
2 years ago
May 02, 2022
|
Sell 8.26 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 5857
|
1.41 USD |
|
2 years ago
Mar 21, 2022
|
Sell 3.58 K
USD
|
Paterson Dan
President and COO
|
- 2818
|
1.27 USD |
|
2 years ago
Mar 21, 2022
|
Sell 4.45 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 3507
|
1.27 USD |
|
2 years ago
Mar 21, 2022
|
Sell 1.79 K
USD
|
Gagnon Robert E.
Chief Financial Officer
|
- 1409
|
1.27 USD |
|
2 years ago
Jan 31, 2022
|
Sell 8.43 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 5695
|
1.48 USD |
|
3 years ago
Jan 03, 2022
|
Sell 53.4 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 26033
|
2.05 USD |
|
3 years ago
Jan 03, 2022
|
Sell 40.2 K
USD
|
Gagnon Robert E.
Chief Financial Officer
|
- 19612
|
2.05 USD |
|
3 years ago
Jan 03, 2022
|
Sell 48.2 K
USD
|
Paterson Dan
President and COO
|
- 23534
|
2.05 USD |
|
3 years ago
Dec 20, 2021
|
Sell 31.1 K
USD
|
Stuglik Brian M
Chief Executive Officer
|
- 13682
|
2.27 USD |
|
3 years ago
Dec 20, 2021
|
Sell 25 K
USD
|
Paterson Dan
President and COO
|
- 10994
|
2.27 USD |
|
3 years ago
Dec 20, 2021
|
Sell 12.5 K
USD
|
Gagnon Robert E.
Chief Financial Officer
|
- 5497
|
2.27 USD |
|
4 years ago
Dec 04, 2020
|
Bought
108 K USD
|
BARBERICH TIMOTHY J
Director
|
+ 50000
|
2.17 USD |
|
4 years ago
Jun 25, 2020
|
Sell 2.22 M
USD
|
RA CAPITAL MANAGEMENT, L.P.
10 percent owner
|
- 1161300
|
1.9116 USD |
|
4 years ago
Apr 27, 2020
|
Sell 3 M
USD
|
RA CAPITAL MANAGEMENT, L.P.
10 percent owner
|
- 1301300
|
2.307 USD |
|
5 years ago
Mar 15, 2019
|
Bought
106 K USD
|
BARBERICH TIMOTHY J
Director
|
+ 33000
|
3.21 USD |
|
6 years ago
Sep 28, 2018
|
Bought
36.6 K USD
|
BARBERICH TIMOTHY J
Director
|
+ 5000
|
7.31 USD |
|
6 years ago
Sep 28, 2018
|
Bought
21.9 K USD
|
Lobacki Joseph M
Executive VP & CCO
|
+ 3000
|
7.3 USD |
|
6 years ago
Sep 28, 2018
|
Bought
21 K USD
|
Paterson Dan
Chief Operating Officer
|
+ 3000
|
7 USD |
|
6 years ago
Sep 28, 2018
|
Bought
14 K USD
|
Forrester Robert
President and CEO
|
+ 2000
|
7 USD |
|
6 years ago
Sep 28, 2018
|
Bought
30 K USD
|
Kauffman Michael
Director
|
+ 4000
|
7.49 USD |
|
6 years ago
Sep 28, 2018
|
Bought
4.38 K USD
|
Stuglik Brian M
Director
|
+ 600
|
7.3 USD |
|
6 years ago
Sep 28, 2018
|
Bought
730 USD
|
Stuglik Brian M
Director
|
+ 100
|
7.3 USD |
|
6 years ago
Sep 28, 2018
|
Bought
2.19 K USD
|
Stuglik Brian M
Director
|
+ 300
|
7.31 USD |
|
6 years ago
Sep 27, 2018
|
Bought
70 K USD
|
Forrester Robert
President and CEO
|
+ 10000
|
7 USD |
|
6 years ago
Sep 27, 2018
|
Bought
3.5 K USD
|
Forrester Robert
President and CEO
|
+ 500
|
7 USD |
|
6 years ago
Sep 27, 2018
|
Bought
8.45 K USD
|
Paterson Dan
Chief Operating Officer
|
+ 1200
|
7.04 USD |
|
6 years ago
Sep 27, 2018
|
Bought
5.61 K USD
|
Paterson Dan
Chief Operating Officer
|
+ 800
|
7.01 USD |
|
6 years ago
Jun 08, 2018
|
Bought
44.6 K USD
|
Lobacki Joseph M
Executive VP & CCO
|
+ 7700
|
5.79 USD |
|
6 years ago
Jun 08, 2018
|
Bought
17.9 K USD
|
Bloom Steven H.
Chief Strategy Officer
|
+ 3000
|
5.98 USD |
|
7 years ago
Dec 05, 2017
|
Bought
239 K USD
|
BARBERICH TIMOTHY J
Director
|
+ 60538
|
3.95 USD |
|
7 years ago
May 15, 2017
|
Bought
73.5 K USD
|
BARBERICH TIMOTHY J
Director
|
+ 30000
|
2.45 USD |
|
9 years ago
Mar 19, 2015
|
Sell 10.2 K
USD
|
Kauffman Michael
Director
|
- 930
|
10.959 USD |
|
9 years ago
Aug 24, 2015
|
Sell 13.4 K
USD
|
Kauffman Michael
Director
|
- 2070
|
6.461 USD |
|
9 years ago
Jun 29, 2015
|
Bought
6.95 K USD
|
Singh Monica
General Counsel
|
+ 1000
|
6.95 USD |
|
9 years ago
Jun 29, 2015
|
Bought
3.56 K USD
|
GREEN JOHN B
Chief Financial Officer
|
+ 500
|
7.12 USD |
|
9 years ago
Jun 29, 2015
|
Bought
14.2 K USD
|
Forrester Robert
President and CEO
|
+ 2000
|
7.105 USD |
|
9 years ago
Jun 26, 2015
|
Bought
3.7 K USD
|
GREEN JOHN B
Chief Financial Officer
|
+ 500
|
7.3919 USD |
|
9 years ago
Jun 18, 2015
|
Bought
8.04 K USD
|
Paterson Dan
Chief Operating Officer
|
+ 1000
|
8.045 USD |
|
9 years ago
Jun 17, 2015
|
Bought
7.97 K USD
|
Forrester Robert
President and CEO
|
+ 1000
|
7.97 USD |
|
9 years ago
Jan 28, 2015
|
Bought
250 K USD
|
BARBERICH TIMOTHY J
Director
|
+ 38462
|
6.5 USD |
|
9 years ago
Jan 28, 2015
|
Bought
8 M USD
|
Westphal Christoph H
Executive Chairman
|
+ 1230769
|
6.5 USD |
|
10 years ago
Dec 23, 2014
|
Bought
122 K USD
|
TERMEER HENRI A
Director
|
+ 15000
|
8.1083 USD |
|
10 years ago
Dec 23, 2014
|
Bought
114 K USD
|
TERMEER HENRI A
Director
|
+ 14000
|
8.1078 USD |
|
10 years ago
Dec 29, 2014
|
Bought
85.4 K USD
|
Phanstiel S. Louise
Director
|
+ 10000
|
8.5435 USD |
|
10 years ago
Dec 29, 2014
|
Bought
6.45 K USD
|
Horobin Joanna
Chief Medical Officer
|
+ 750
|
8.6 USD |
|
10 years ago
Dec 26, 2014
|
Bought
21.4 K USD
|
SHERWIN STEPHEN A
Director
|
+ 2500
|
8.558 USD |
|
10 years ago
Dec 24, 2014
|
Bought
24.9 K USD
|
FRIEDMAN PAUL A
Director
|
+ 3000
|
8.3108 USD |
|
10 years ago
Dec 23, 2014
|
Bought
72.8 K USD
|
TERMEER HENRI A
Director
|
+ 9000
|
8.0888 USD |
|
10 years ago
Dec 23, 2014
|
Bought
81.7 K USD
|
TERMEER HENRI A
Director
|
+ 10100
|
8.0938 USD |
|
10 years ago
Dec 23, 2014
|
Bought
4.08 K USD
|
GREEN JOHN B
Chief Financial Officer
|
+ 500
|
8.17 USD |
|
10 years ago
Dec 23, 2014
|
Bought
8.09 K USD
|
Singh Monica
General Counsel
|
+ 1000
|
8.089 USD |
|
10 years ago
Dec 19, 2014
|
Bought
12.8 K USD
|
Westphal Christoph H
Executive Chairman
|
+ 1500
|
8.5 USD |
|
10 years ago
Dec 19, 2014
|
Bought
17 K USD
|
Paterson Dan
Chief Operating Officer
|
+ 2000
|
8.5199 USD |
|
10 years ago
Dec 19, 2014
|
Bought
8.66 K USD
|
Forrester Robert
President and CEO
|
+ 1000
|
8.66 USD |
|
10 years ago
Nov 11, 2014
|
Bought
22.9 K USD
|
Lawton Alison Frances
Director
|
+ 2500
|
9.1692 USD |
|
10 years ago
Sep 17, 2014
|
Bought
27.3 K USD
|
Kauffman Michael
Director
|
+ 3000
|
9.0999 USD |
|
10 years ago
May 30, 2014
|
Bought
9.9 K USD
|
BARBERICH TIMOTHY J
Director
|
+ 1000
|
9.895 USD |
|
10 years ago
May 20, 2014
|
Bought
8.37 K USD
|
ALDRICH RICHARD
Director
|
+ 1000
|
8.37 USD |
|
10 years ago
May 15, 2014
|
Bought
7.47 K USD
|
Paterson Dan
Chief Business Officer
|
+ 1000
|
7.467 USD |
|
10 years ago
May 14, 2014
|
Bought
15.1 K USD
|
Westphal Christoph H
Executive Chairman
|
+ 2000
|
7.56 USD |
|
10 years ago
May 13, 2014
|
Bought
7.74 K USD
|
GREEN JOHN B
Chief Financial Officer
|
+ 1000
|
7.74 USD |
|
10 years ago
May 13, 2014
|
Bought
7.62 K USD
|
Pachter Jonathan
VP, Head of Research
|
+ 1000
|
7.62 USD |
|
10 years ago
May 13, 2014
|
Bought
7.62 K USD
|
Forrester Robert
President and CEO
|
+ 1000
|
7.62 USD |
|
11 years ago
Nov 18, 2013
|
Bought
9.6 K USD
|
Westphal Christoph H
director, 10 percent owner:
|
+ 1000
|
9.602 USD |
|
11 years ago
Nov 11, 2013
|
Bought
10.9 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
10.93 USD |
|
11 years ago
Nov 04, 2013
|
Bought
10.5 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
10.51 USD |
|
11 years ago
Oct 28, 2013
|
Bought
11.3 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
11.26 USD |
|
11 years ago
Oct 21, 2013
|
Bought
12.6 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
12.57 USD |
|
11 years ago
Oct 14, 2013
|
Bought
10.6 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
10.56 USD |
|
11 years ago
Oct 07, 2013
|
Bought
11.5 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
11.53 USD |
|
11 years ago
Sep 30, 2013
|
Bought
12.6 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
12.55 USD |
|
11 years ago
Sep 23, 2013
|
Bought
13.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
13.17 USD |
|
11 years ago
Sep 16, 2013
|
Bought
13.8 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
13.81 USD |
|
11 years ago
Sep 09, 2013
|
Bought
14 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
14.04 USD |
|
11 years ago
Sep 03, 2013
|
Bought
14.1 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
14.07 USD |
|
11 years ago
Aug 26, 2013
|
Bought
14.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
14.21 USD |
|
11 years ago
Aug 19, 2013
|
Bought
13.4 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
13.45 USD |
|
11 years ago
Aug 12, 2013
|
Bought
14.8 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
14.75 USD |
|
11 years ago
Aug 05, 2013
|
Bought
15.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
15.25 USD |
|
11 years ago
Jul 29, 2013
|
Bought
15.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
15.15 USD |
|
11 years ago
Jul 24, 2013
|
Bought
16.4 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
16.39 USD |
|
11 years ago
Jul 15, 2013
|
Bought
17.2 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
17.19 USD |
|
11 years ago
Jul 08, 2013
|
Bought
14.7 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
14.69 USD |
|
11 years ago
Jul 01, 2013
|
Bought
14.1 K USD
|
ALDRICH RICHARD
director, 10 percent owner:
|
+ 1000
|
14.11 USD |
|
11 years ago
Jun 13, 2013
|
Bought
11.4 K USD
|
Forrester Robert
President and COO
|
+ 1000
|
11.394 USD |
|
11 years ago
Jun 12, 2013
|
Bought
222 K USD
|
CHP III LP
10 percent owner
|
+ 23171
|
9.5993 USD |
|
11 years ago
Jun 11, 2013
|
Bought
230 K USD
|
CHP III LP
10 percent owner
|
+ 25000
|
9.2191 USD |
|
11 years ago
Jun 12, 2013
|
Bought
222 K USD
|
CLARKE JOHN K
Director
|
+ 23171
|
9.5993 USD |
|
11 years ago
Jun 12, 2013
|
Bought
43.2 K USD
|
Phanstiel S. Louise
Director
|
+ 4500
|
9.6005 USD |
|
11 years ago
Jun 12, 2013
|
Bought
56.7 K USD
|
TERMEER HENRI A
Director
|
+ 5823
|
9.7443 USD |
|
11 years ago
Jun 11, 2013
|
Bought
75 K USD
|
Phanstiel S. Louise
Director
|
+ 8000
|
9.3722 USD |
|
11 years ago
Jun 10, 2013
|
Bought
36.6 K USD
|
Phanstiel S. Louise
Director
|
+ 4000
|
9.1625 USD |
|
11 years ago
Jun 11, 2013
|
Bought
230 K USD
|
CLARKE JOHN K
Director
|
+ 25000
|
9.2191 USD |
|
11 years ago
Jun 11, 2013
|
Bought
106 K USD
|
TERMEER HENRI A
Director
|
+ 11356
|
9.3537 USD |
|
11 years ago
Jun 07, 2013
|
Bought
9.06 K USD
|
Westphal Christoph H
Chief Executive Officer
|
+ 1000
|
9.056 USD |
|
11 years ago
May 21, 2013
|
Bought
7.39 K USD
|
Westphal Christoph H
Chief Executive Officer
|
+ 800
|
9.2412 USD |
|
11 years ago
May 13, 2013
|
Bought
243 K USD
|
CLARKE JOHN K
Director
|
+ 25000
|
9.735 USD |
|
11 years ago
May 13, 2013
|
Bought
243 K USD
|
CHP III LP
10 percent owner
|
+ 25000
|
9.735 USD |
|
11 years ago
May 03, 2013
|
Bought
7.86 K USD
|
Westphal Christoph H
Chief Executive Officer
|
+ 800
|
9.8281 USD |
|
11 years ago
May 01, 2013
|
Bought
96.6 K USD
|
CLARKE JOHN K
Director
|
+ 10000
|
9.6622 USD |
|
11 years ago
May 01, 2013
|
Bought
96.6 K USD
|
CHP III LP
10 percent owner
|
+ 10000
|
9.662 USD |
|
11 years ago
Apr 17, 2013
|
Bought
53.5 K USD
|
CLARKE JOHN K
Director
|
+ 5631
|
9.499 USD |
|
11 years ago
Apr 17, 2013
|
Bought
7.62 K USD
|
Westphal Christoph H
Chief Executive Officer
|
+ 800
|
9.53 USD |
|
11 years ago
Apr 17, 2013
|
Bought
53.5 K USD
|
CHP III LP
10 percent owner
|
+ 5631
|
9.499 USD |
|
11 years ago
Mar 21, 2013
|
Bought
7.23 K USD
|
Westphal Christoph H
Chief Executive Officer
|
+ 800
|
9.04 USD |
|
11 years ago
Mar 05, 2013
|
Bought
7.58 K USD
|
Westphal Christoph H
Chief Executive Officer
|
+ 800
|
9.47 USD |
|
11 years ago
Jan 29, 2013
|
Bought
3 K USD
|
Westphal Christoph H
Chief Executive Officer
|
+ 300
|
10 USD |
|
12 years ago
Jan 02, 2013
|
Bought
7.78 K USD
|
Westphal Christoph H
President and C.E.O.
|
+ 800
|
9.73 USD |
|
12 years ago
Dec 18, 2012
|
Bought
48.7 K USD
|
CHP III LP
10 percent owner
|
+ 6193
|
7.87 USD |
|
12 years ago
Dec 18, 2012
|
Bought
48.7 K USD
|
CLARKE JOHN K
Director
|
+ 6193
|
7.87 USD |
|
12 years ago
Jan 27, 2012
|
Bought
48.7 K USD
|
CHP III LP
10 percent owner
|
+ 6193
|
7.87 USD |
|
12 years ago
Feb 01, 2012
|
Bought
1 M USD
|
MPM BIOVENTURES V LLC
|
+ 100000
|
10 USD |
|
12 years ago
Feb 01, 2012
|
Bought
1 M USD
|
Bessemer Venture Partners VII L.P.
director, 10 percent owner:
|
+ 100000
|
10 USD |
|
12 years ago
Feb 01, 2012
|
Bought
0 USD
|
Kraus Stephen
Director
|
+ 0
|
10 USD |
|
12 years ago
Feb 01, 2012
|
Bought
963 K USD
|
GADICKE ANSBERT
Director
|
+ 96260
|
10 USD |
|
12 years ago
Feb 01, 2012
|
Bought
37.4 K USD
|
GADICKE ANSBERT
Director
|
+ 3740
|
10 USD |
|
12 years ago
Feb 01, 2012
|
Bought
2.5 M USD
|
CLARKE JOHN K
Director
|
+ 250000
|
10 USD |
|
12 years ago
Jan 27, 2012
|
Bought
2.5 M USD
|
CHP III LP
10 percent owner
|
+ 250000
|
10 USD |
7. News
Verastem: Planning The PDUFA Run-Up
Verastem, Inc.'s NDA for avutometinib and defactinib in recurrent KRAS-mutant LGSOC has been accepted by the FDA, with a PDUFA date set for June 30, 2025. The combination therapy shows promising Phase II RAMP 201 results, with a 31% ORR and significant tumor size reduction, potentially positioning Verastem as a commercial-stage company by 2025. The LGSOC market is projected to reach $363.7M by 2034, with Verastem's therapy poised to capture a significant share due to the lack of approved treatments.
seekingalpha.com
- 2 weeks ago
Verastem: BLA Acceptance Puts Key Goals In Sight
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Financially, VSTM has limited cash reserves, with only 4-5 quarters of operating funds, posing a risk if there are approval delays. The market size for their therapy is uncertain, with potential revenues ranging from $85.7 million to $686 million annually.
seekingalpha.com
- 2 weeks ago
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.
zacks.com
- 2 weeks ago
Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?
On Monday, the FDA accepted for review the New Drug Application under the accelerated approval pathway for Verastem Oncology's VSTM avutometinib.
benzinga.com
- 2 weeks ago
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib, an oral FAK inhibitor, for the treatment of adult patients with recurrent low-grade serous ovarian cancer (LGSOC), wh.
businesswire.com
- 2 weeks ago
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small cell lung cancer (NSCLC). No dose-limiting toxicities (DLTs) have been observed in the triplet combination. RAMP 203 continues to progress, with additional enroll.
businesswire.com
- 1 month ago
Verastem: Preparing For Upcoming Catalysts
Verastem's avutometinib and defactinib show promising clinical progress for recurrent KRAS-mutant LGSOC, with potential FDA approval and market launch by mid-2025. The company's strong cash position and strategic focus on RAS-driven cancers offer significant growth opportunities without imminent dilution risks. Upcoming catalysts include FDA filing decisions, interim data from NSCLC and pancreatic cancer trials, and potential commercial launch, driving Verastem's bullish outlook.
seekingalpha.com
- 1 month ago
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3rd at 11:15 am EST. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.verastem.com. A repla.
businesswire.com
- 1 month ago
Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences: 2024 Truist Securities BioPharma Symposium on November 7, 2024 Guggenheim Healthcare Innovation Conference; fireside chat on Wednesday, November 13, 2024 at 9:00 am EDT A live webcast of the fireside chat can be accessed under “Events & Pr.
businesswire.com
- 2 months ago
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from the Phase 2 RAMP 201 (ENGOTov60/GOG3052) clinical trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data were published as a late-breaking abstract and additional detaile.
businesswire.com
- 3 months ago
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting taking place October 16-18, 2024 in Dublin, Ireland. The l.
businesswire.com
- 3 months ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 109,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options h.
businesswire.com
- 3 months ago
8. Profile
Summary
Verastem, Inc. VSTM
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 237 M
Dividend Yield
0.00%
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Contact
117 Kendrick Street, Needham, MA, 02494
https://www.verastem.com
IPO
Date
Jan. 27, 2012
Employees
73
Officers
Ms. Cathy Carew
Chief Organizational Effectiveness Officer
Mr. Michael Crowther
Chief Commercial & Strategy Officer
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Mr. Daniel Calkins
Chief Financial Officer and Principal Accounting & Financial Officer
Mr. Richard H. Aldrich M.B.A.
Founder and Consultant
Mr. Nate Sanburn
Chief Business Officer
Mr. Daniel W. Paterson
President, Chief Executive Officer & Director
Dr. Michelle Dipp M.D., Ph.D.
Co-Founder
Dr. Piyush B. Gupta Ph.D.
Co-Founder